25.90
0.02 (0.08%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Upstream Bio, Inc. | - | - |
Stockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | 1.5 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.00 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (“TSLP”), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AI UPSTREAM LLC | 23.00 | - | 5,494,410 | 126,371,430 |
| CHIMOVITS EREZ | 23.00 | - | 4,434,789 | 102,000,147 |
| ORBIMED ADVISORS LLC | 23.00 | - | 4,434,789 | 102,000,147 |
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I | 23.00 | - | 894,733 | 20,578,859 |
| Aggregate Net Quantity | 15,258,721 | |||
| Aggregate Net Value ($) | 350,950,583 | |||
| Aggregate Avg. Buy ($) | 23.00 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I | 15 Oct 2024 | Acquired (+) | 894,733 | 23.00 | 20,578,859 | |
| AI UPSTREAM LLC | 15 Oct 2024 | Buy (+) | 1,175,000 | 23.00 | 27,025,000 | |
| AI UPSTREAM LLC | 15 Oct 2024 | Acquired (+) | 4,319,410 | 23.00 | 99,346,430 | |
| ORBIMED ADVISORS LLC | Director | 15 Oct 2024 | Acquired (+) | 3,609,789 | 23.00 | 83,025,147 |
| ORBIMED ADVISORS LLC | Director | 15 Oct 2024 | Buy (+) | 825,000 | 23.00 | 18,975,000 |
| CHIMOVITS EREZ | Director | 15 Oct 2024 | Acquired (+) | 3,609,789 | 23.00 | 83,025,147 |
| CHIMOVITS EREZ | Director | 15 Oct 2024 | Buy (+) | 825,000 | 23.00 | 18,975,000 |
| Date | Type | Details |
|---|---|---|
| 15 Oct 2024 | Announcement | Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |